Anaplastična limfomna kinaza

Anaplastična limfomna receptorska tirozinska kinaza
	; Ljudska anaplastična limfomna kinaza u kompleksu sa krizotinibom. PDB 2xp2
Dostupne strukture
	2KUP, 2KUQ, 2XB7, 2XBA, 2XP2, 2YFX, 2YHV, 2YJR, 2YJS, 2YS5, 2YT2, 3AOX, 3L9P, 3LCS, 3LCT, 4ANL, 4ANQ, 4ANS, 4CCB, 4CCU, 4CD0, 4DCE, 4FNW, 4FNX, 4FNY, 4FNZ, 4FOB, 4FOC, 4FOD, 4JOA, 4MKC
Identifikatori
Simboli	ALK; CD246; NBLST3
Vanjski ID	OMIM: 105590 MGI: 103305 HomoloGene: 68387 GeneCards: ALK Gene
EC broj	2.7.10.1
Ontologija gena
Molekulska funkcija	• aktivnost NF-kapaB indukujuće kinaze; • aktivnost proteinske tirozinske kinaze; • proteinsko vezivanje;
Ćelijska komponenta	• integralna komponenta ćelijske membrane; • proteinski kompleks; • ekstracelularni vezikularni eksosom;
Biološki proces	• aktivacija MAPK aktivnosti; • prenos signala; • signalni put transmembranske receptorske proteinske tirozinske kinaze;
Pregled RNK izražavanja
	podaci
Ortolozi

edit

Anaplastična limfomna kinaza (ALK, ALK tirozinski kinazni receptor, CD246, klaster diferencijacije 246) enzim je koji je kod ljudi kodiran ALK genom.^[2]^[3]

Povezano

Klasteri diferencijacije

Reference

↑ Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP (September 2011). „Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)”. J. Med. Chem. 54 (18): 6342–63. DOI:10.1021/jm2007613. PMID 21812414.
↑ Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT (Apr 1994). „Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma”. Science 263 (5151): 1281–4. DOI:10.1126/science.8122112. PMID 8122112.
↑ „Entrez Gene: ALK anaplastic lymphoma kinase (Ki-1)”.

Literatura

Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugières L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G (March 1998). „ALK-positive lymphoma: a single disease with a broad spectrum of morphology”. Blood 91 (6): 2076–84. PMID 9490693.
Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F, Delsol G, Morris SW (December 2004). „The emerging normal and disease-related roles of anaplastic lymphoma kinase”. Cell. Mol. Life Sci. 61 (23): 2939–53. DOI:10.1007/s00018-004-4275-9. PMID 15583856.
Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T (April 1996). „Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)”. Proc. Natl. Acad. Sci. U.S.A. 93 (9): 4181–6. DOI:10.1073/pnas.93.9.4181. PMC 39508. PMID 8633037.
Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T (January 1997). „Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system”. Oncogene 14 (4): 439–49. DOI:10.1038/sj.onc.1200849. PMID 9053841.
Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP (May 1997). „ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)”. Oncogene 14 (18): 2175–88. DOI:10.1038/sj.onc.1201062. PMID 9174053.
Bai RY, Dieter P, Peschel C, Morris SW, Duyster J (December 1998). „Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity”. Mol. Cell. Biol. 18 (12): 6951–61. PMC 109278. PMID 9819383.
Hernández L, Pinyol M, Hernández S, et al. (1999). „TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations”. Blood 94 (9): 3265–8. PMID 10556217.
Souttou B, Carvalho NB, Raulais D, Vigny M (March 2001). „Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway”. J. Biol. Chem. 276 (12): 9526–31. DOI:10.1074/jbc.M007333200. PMID 11121404.
Simonitsch I, Polgar D, Hajek M, Duchek P, Skrzypek B, Fassl S, Lamprecht A, Schmidt G, Krupitza G, Cerni C (June 2001). „The cytoplasmic truncated receptor tyrosine kinase ALK homodimer immortalizes and cooperates with ras in cellular transformation”. FASEB J. 15 (8): 1416–8. DOI:10.1096/fj.00-0678fje. PMID 11387242.
Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G (February 2002). „Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death”. Oncogene 21 (7): 1038–47. DOI:10.1038/sj.onc.1205152. PMID 11850821.
Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C (March 2002). „ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes”. Blood 99 (6): 2100–6. DOI:10.1182/blood.V99.6.2100. PMID 11877285.
Bonvini P, Gastaldi T, Falini B, Rosolen A (March 2002). „Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin”. Cancer Res. 62 (5): 1559–66. PMID 11888936.
Hernández L, Beà S, Bellosillo B, Pinyol M, Falini B, Carbone A, Ott G, Rosenwald A, Fernández A, Pulford K, Mason D, Morris SW, Santos E, Campo E (April 2002). „Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity”. Am. J. Pathol. 160 (4): 1487–94. DOI:10.1016/S0002-9440(10)62574-6. PMC 1867210. PMID 11943732.
ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ, Oudejans JJ (June 2002). „Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma”. Blood 99 (12): 4540–6. DOI:10.1182/blood.V99.12.4540. PMID 12036886.
Dirks WG, Fähnrich S, Lis Y, Becker E, MacLeod RA, Drexler HG (July 2002). „Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines”. Int. J. Cancer 100 (1): 49–56. DOI:10.1002/ijc.10435. PMID 12115586.

Vanjske veze

[pmid21812414-1] Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP (September 2011). „Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)”. J. Med. Chem. 54 (18): 6342–63. DOI:10.1021/jm2007613. PMID 21812414.

[pmid8122112-2] Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT (Apr 1994). „Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma”. Science 263 (5151): 1281–4. DOI:10.1126/science.8122112. PMID 8122112.

[entrez-3] „Entrez Gene: ALK anaplastic lymphoma kinase (Ki-1)”.

[1]

[2]

[3]

p r u Proteini: klasteri diferencijacije (vidi isto spisak ljudskih klastera diferencijacije)
1-50	CD1 (a-c, 1A, 1D, 1E) • CD2 • CD3 (γ, δ, ε) • CD4 • CD5 • CD6 • CD7 • CD8 (a) • CD9 • CD10 • CD11 (a, b, c) • CD13 • CD14 • CD15 • CD16 (A, B) • CD18 • CD19 • CD20 • CD21 • CD22 • CD23 • CD24 • CD25 • CD26 • CD27 • CD28 • CD29 • CD30 • CD31 • CD32 (A, B) • CD33 • CD34 • CD35 • CD36 • CD37 • CD38 • CD39 • CD40 • CD41 • CD42 (a, b, c, d) • CD43 • CD44 • CD45 • CD46 • CD47 • CD48 • CD49 (a, b, c, d, e, f) • CD50
51-100	CD51 • CD52 • CD53 • CD54 • CD55 • CD56 • CD57 • CD58 • CD59 • CD61 • CD62 (E, L, P) • CD63 • CD64 (A, B, C) • CD66 (a, b, c, d, e, f) • CD68 • CD69 • CD70 • CD71 • CD72 • CD73 • CD74 • CD78 • CD79 (a, b) • CD80 • CD81 • CD82 • CD83 • CD84 • CD85 (a, d, e, h, j, k) • CD86 • CD87 • CD88 • CD89 • CD90 • CD91- CD92 • CD93 • CD94 • CD95 • CD96 • CD97 • CD98 • CD99 • CD100
101-150	CD101 • CD102 • CD103 • CD104 • CD105 • CD106 • CD107 (a, b) • CD108 • CD109 • CD110 • CD111 • CD112 • CD113 • CD114 • CD115 • CD116 • CD117 • CD118 • CD119 • CD120 (a, b) • CD121 (a, b) • CD122 • CD123 • CD124 • CD125 • CD126 • CD127 • CD129 • CD130 • CD131 • CD132 • CD133 • CD134 • CD135 • CD136 • CD137 • CD138 • CD140b • CD141 • CD142 • CD143 • CD144 • CD146 • CD147 • CD148 • CD150
151-200	CD151 • CD152 • CD153 • CD154 • CD155 • CD156 (a, b, c) • CD157 • CD158 (a, d, e, i, k) • CD159 (a, c) • CD160 • CD161 • CD162 • CD163 • CD164 • CD166 • CD167 (a, b) • CD168 • CD169 • CD170 • CD171 • CD172 (a, b, g) • CD174 • CD177 • CD178 • CD179 (a, b) • CD181 • CD182 • CD183 • CD184 • CD185 • CD186 • CD191 • CD192 • CD193 • CD194 • CD195 • CD196 • CD197 • CDw198 • CDw199 • CD200
201-250	CD201 • CD202b • CD204 • CD205 • CD206 • CD207 • CD208 • CD209 • CDw210 (a, b) • CD212 • CD213a (1, 2) • CD217 • CD218 (a, b) • CD220 • CD221 • CD222 • CD223 • CD224 • CD225 • CD226 • CD227 • CD228 • CD229 • CD230 • CD233 • CD234 • CD235 (a, b) • CD236 • CD238 • CD239 • CD240CE • CD241 • CD243 • CD244 • CD246 • CD247- CD248 • CD249
251-300	CD252 • CD253 • CD254 • CD256 • CD257 • CD258 • CD261 • CD262 • CD264 • CD265 • CD266 • CD267 • CD268 • CD269 • CD271 • CD272 • CD273 • CD274 • CD275 • CD276 • CD278 • CD279 • CD280 • CD281 • CD282 • CD283 • CD284 • CD286 • CD288 • CD289 • CD290 • CD292 • CDw293 • CD294 • CD295 • CD297 • CD298 • CD299
301-350	CD300A • CD301 • CD302 • CD303 • CD304 • CD305 • CD306 • CD307 • CD309 • CD312 • CD314 • CD315 • CD316 • CD317 • CD318 • CD320 • CD321 • CD322 • CD324 • CD325 • CD326 • CD328 • CD329 • CD331 • CD332 • CD333 • CD334 • CD335 • CD336 • CD337 • CD338 • CD339 • CD340 • CD344 • CD349 • CD350